RSS   Newsletter   Contact   Advertise with us

AstraZeneca Q3 pre-tax profit up, product sales down

Staff Writer | November 9, 2017
AstraZeneca reported that its third-quarter profit before tax increased 10 percent to $746 million from $676 million last year.
AstraZeneca
AstraZeneca   Core earnings per share were $1.12
Profit after tax, meanwhile, fell 35 percent to $649 million from $995 million a year ago. Earnings per share were $0.54, down from $0.80 a year ago.

Core earnings per share were $1.12, down 15 percent. Core operating profit increased 9 percent to $1.85 billion.

Total revenue was $6.23 billion, up 9 percent from $5.70 billion last year. Revenues grew 10 percent on a constant exchange rate.

Product Sales, meanwhile, dropped 3 percent to $4.88 billion.

Looking ahead, for fiscal 2017, the company now anticipates a 2017 Core earnings per share performance towards the favourable end of the guidance range of a low to mid teens percentage decline.

Total revenue for the year is still expected to a low to mid single-digit percentage decline.


 

MORE INSIDE POST